|
Volume
20 Number 4
April 2018
|
|
Home
>
Publications
>
Neuro-Oncology
Reviews >
Volume
20, Year 2018 >
Number 4, April
|
|
|
|
|
|
Vanderbeek AM, Rahman R, Fell G, Ventz S, Chen T, Redd R,
Parmigiani G, Cloughesy TF, Wen PY, Trippa L, Alexander BM.
The
clinical trials landscape for glioblastoma: is it adequate to
develop new treatments?
Neuro Oncol. 2018 Apr 5,
2018;20(8):1034-1043→.
doi: 10.1093/neuonc/noy027→.
PMID: 29518210→.
Meta-analysis.
→
|
|
|
|
Lu VM, Jue TR, McDonald KL, Rovin RA.
The
survival effect of repeat surgery at glioblastoma recurrence and
its trend: A systematic review and meta-analysis.
World
Neurosurg. 2018 Apr 11. pii: S1878-8750(18)30732-0. doi:
10.1016/j.wneu.2018.04.016. Source
|
Abstract
|
Similar
articles
|
|
|
|
|
|
Nandu H, Wen PY, Huang RY.
Imaging in neuro-oncology.
Ther Adv Neurol Disord. 2018 Feb 28;11:1756286418759865.
doi: 10.1177/1756286418759865. eCollection 2018.
Source
.
Similar
articles
|
|
|
|
▲
|
|
Levin VA, Ellingson BM.
Understanding Brain Penetrance of
Anticancer Drugs.
Neuro Oncol. 2018 Feb 21. doi:
10.1093/neuonc/noy018. [Epub ahead of print]
Source
.
Similar
articles
|
|
|
|
Thust SC, Heiland S, Falini A, Jäger HR, Waldman AD, Sundgren
PC, Godi C, Katsaros VK, Ramos A, Bargallo N, Vernooij MW, Yousry
T, Bendszus M, Smits M.
Glioma imaging in Europe: A
survey of 220 centres and recommendations for best clinical
practice.
Eur Radiol. 2018 Mar 13. doi:
10.1007/s00330-018-5314-5. [Epub ahead of print]
Source
.
Similar
articles
|
|
|
|
|
|
Mandonnet E, Duffau H.
An attempt to conceptualize the
individual onco-functional balance: Why a standardized treatment
is an illusion for diffuse low-grade glioma patients.
Crit
Rev Oncol Hematol. 2018 Feb;122:83-91. doi:
10.1016/j.critrevonc.2017.12.008. Epub 2017 Dec 13.
Source
.
Similar
articles
|
|
|
|
▲
|
|
|
|
|
|
Cai X, Sughrue ME.
Glioblastoma: new therapeutic
strategies to address cellular and genomic complexity.
Oncotarget. 2017 Dec 20;9(10):9540-9554. doi:
10.18632/oncotarget.23476. eCollection 2018 Feb 6.
Source
.
Similar
articles
|
|
|
|
Coleman N, Ameratunga M, Lopez J.
Development of
Molecularly Targeted Agents and Immunotherapies in Glioblastoma: A
Personalized Approach.
Clin Med Insights Oncol. 2018 Feb
26;12:1179554918759079. doi: 10.1177/1179554918759079. eCollection
2018.
Source
.
Similar
articles
|
|
|
|
Jindal V.
Role of Chimeric Antigen Receptor T Cell
Therapy in Glioblastoma Multiforme.
Mol Neurobiol. 2018
Mar 9. doi: 10.1007/s12035-018-0978-z. [Epub ahead of print]
Source
.
Similar
articles
|
|
|
|
Prinzing BL, Gottschalk SM, Krenciute G.
CAR T-cell
therapy for glioblastoma: ready for the next round of clinical
testing?
Expert Rev Anticancer Ther. 2018
May;18(5):451-461. doi: 10.1080/14737140.2018.1451749. Epub 2018
Mar 16.
Source
.
Similar
articles
|
|
|
|
Vanderbeek AM, Rahman R, Fell G, Ventz S, Chen T, Redd R,
Parmigiani G, Cloughesy TF, Wen PY, Trippa L, Alexander BM.
The
clinical trials landscape for glioblastoma: is it adequate to
develop new treatments?
Neuro Oncol. 2018 Mar 6. doi:
10.1093/neuonc/noy027. [Epub ahead of print]
Source
.
Similar
articles
|
|
|
|
▲
|
|
|
|
|
|
Chastagner P.
Medulloblastoma: A turning point from
fundamental advances to improved survival and decreased sequelae.
Neurochirurgie. 2018 Feb 12. pii: S0028-3770(17)30182-0.
doi: 10.1016/j.neuchi.2017.10.006. [Epub ahead of print]
Source
.
Similar
articles
|
|
|
|
▲
|
|
|
